The Luton and Dunstable Hospital, -Luton, Bedfordshire, England THIOPENTONE was introduced to clinical anaesthesia by Lundy in 1934 and the first reports of its use appeared in the following year (Lundy, 1935; Lundy and Tovell, 1935) . Since then, thiopentone has almost entirely superseded other intravenous agents and has become the standard agent for inducing anaesthesia. It is not, however, without certain dangers. The main disadvantages are the occasional occurrence of laryngeal spasm (Lee, 1953; Dundee, 1956 ) and the ease with which respiratory depression due to overdosage can be produced. Another objection to thiopentone is that, following induction and a brief period of anaesthesia, the patients often have a relatively prolonged period when they are drowsy and confused and in a state described by Lundy (1935) as resembling alcoholic inebriation.
Research workers have been constantly seeking other similar drugs which.would show a shorter recovery period with less postanaesthetic confusion, and buthalitone was introduced as such a drug. Claims have also been made that the incidence of respiratory depression and vagotonic effects is less with this drug than with thiopentone (Davidson and Love, 1956) .
Buthalitone was first prepared by Miller et al. (1936) but it was not used clinically until 1954 when Weese and Koss reported on a clinical trial of 350 cases. This has been followed by numerous reports of other clinical trials in which this drug has been used (Dietmann, 1954; Pestel, 1954; Vollmer and Haaf, 1954; Ritter and Schaffer, 1954; Bergentz and Arosenius, 1955; De Cesare and Paoletti, 1955; Nobes, 1955a, b; Ruddell, 1955; Westerborn and Stenberg, 1955; Guldmann, 1956; Manni et al., 1956; Rajagopalan, 1956; Williams, 1956; Young, 1956; Duffield and Ginsberg, 1957; Mostert and Durham, 1957) . Following our investigation into the use of buthalitone sodium in out-patient anaesthesia (1957) , it seemed to us to be reasonable to try usiirt hiopentone under similar conditions and to see whether the claims for buthalitone could be substantiated and to make a comparison between the two drugs.
Both buthalitone and thiopentone are thiobarbiturates, the former being sodium 5-allyl-5-isobutyl-2-thiobarbiturate having the formula:
while the latter is sodium 5-ethyl-5-(l-methylbutyl)-2-thiobarbiturate with the formula:
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\ >CS-Na CH,-CH ' X CO N " C.H, and, like most tbiobarbiturates,' they resemble each other both physically and chemically. Several comparisons of the two drugs have been published and these include experiments in rats, dogs and rabbits by Gruhzit et al. (1937) and in rabbits by Inner (1955) . However, it is sometimes difficult to correlate these findings resulting from animal experiments with those obtained in man due to variations in the response to any given drug between different species. We have therefore confined our investigation and discussion to the comparison of these two drugs in man.
One of the first reports of such a comparison was by Freuchen (1956 ) who compared two series, each of 100 cases; one series having been given thiopentone and the other buthalitone. Most of. these patients, who were undergoing various operations, were premedicated with morphine 10 mg and scopolamine 0.4 mg. Using the drugs for induction and maintenance as required, he found that the average total doses were 15.1 mg per kg body weight (96 mg/stone body weight) for buthalitone and 8.3 mg per kg body weight (52.8 mg/stone body weight) for thiopentone. The average recovery times were 15.7 minutes for buthalitone and 27.8 minutes for thiopentone.
O'Mullane (1957) has reported that, in a preliminary trial with an unspecified number of cases, an average dose of 50 mg/stone (6.3 kg) body weight of buthalitone was equivalent to an average dose of 25 mg/stone body weight of thiopentone. On the other hand, reporting on the e.e.g. changes produced in three volunteers, he found that 75 mg/stone body weight of buthalitone and 25 mg/stone body weight of thiopentone produced comparable depths of anaesthesia as assessed by the method of Kiersey et aL (1951) .
Another two comparisons using volunteers have been carried out by Wyant, Dobkin and Aasheim (1957) , when seven agents were compared in five subjects, and Ek>bkin and , when the same seven agents were compared in seven subjects. The results as regards buthalitone and thiopentone in the first paper were that an average dose of 94.9 mg per stone body weight (14.8 mg/kg body weight) of the former was followed by an average recovery period of 7 minutes whilst the average dose of the latter, 67.3 mg per stone body weight (10.5 mg/kg body weight), produced an average recovery time of 30 minutes. In the second paper, using the same dosage with each drug, viz. 500 mg per square metre of body surface area, buthalitone produced an average of 5 minutes sleep while thiopentone produced an average of 34 minutes sleep.
Keeri-Szant6 and Labarre (1957) report on a series of 37 cases of uterine curettage using buthalitone in intermittant dosage. These were compared with a similar series of 24 cases using intermittent dosage of thiopentone. The total amounts of the drug used averaged 71.4 mg per stone body weight (11.2 mg/kg body weight) for buthalitone and 44.8 mg per stone body weight (7.0 mg/kg body weight) for thiopentone. Murray (1957) has reported upon a clinical trial of buthalitone in 850 cases. A comparison with thiopentone was made in 40 females aged between 16 and 46 years who were undergoing uterine curettage. The dose of each drug was recorded as the average dose per kg body weight per minute. This dose was found to be 2.8 mg for the 20 patients receiving buthalitone and 1.5 mg for those receiving thiopentone.
The only comparison of buthalitone and thiopentone solely in outpatient anaesthesia is that of Simmons and Blanshard (1957) . These workers reported upon a trial in 208 patients, the majority of whom were unpremedicated. The minority who received premedication were given only 0.65 mg atropine. The drugs were given by two techniques: a single dose technique with no supplementation, and a technique involving the use of the thiobarbiturate in intermittent dosage and supplementing it by the administration of nitrous oxide with 20 per cent oxygen. Two dosage rates were used. Initially (Trial Period 1), the dose used was the minimum required to produce hypnosis throughout the operation. Trial Period 2 involved the use of a dosage of thiobarbiturate which produced satisfactory operating conditions. The criteria for recovery were a co-ordinated response to a painful stimulus, verbal accessibility and ability to sit up, and the time of reaching each of these stages was measured. The average dosages of buthalitone and thiopentone used were 5.72 and 4.23 mg per lb. body weight (12.58 and 9.30 mg/kg body weight) respectively in Trial Period 1, and 8.19 and 3.93 mg per lb. body weight (18.01 and 8.64 mg/kg body weight) respectively in Trial Period 2. The results showed a considerable increase of recovery time with thiopentone as compared with buthalitone in Trial Period 1. This increase was much less in Trial Period 2 and was not statistically significant. A high incidence of vomiting, coughing and hiccup with buthalitone and a high incidence of coughing with thiopentone was reported.
METHOD
In our previous investigation (Henderson and Mackett, 1957) , all patients received a single induction dose of buthalitone at the rate of 70 mg per stone body weight (10.9 mg/kg body weight) and anaesthesia was maintained with nitrous oxide 8 litres per minute and oxygen 2 litres per minute. In the present investigation, 100 consecutive cases from the first series were compared with four series, each of 100 cases, having thiopentone as the inducing agent. The dosage rates per stone body weight in the four thiopentone series were 25 mg, 30 mg, 35 mg and 40 mg (3.9 mg, 4.7mg, 5.4 mg and 6.2 mg/kg body weight). Initially, after some trial cases, it was felt that a dosage of 25 mg per stone would be roughly equivalent to our previous rate of 70 mg per stone of buthalitone as regards operating conditions and recovery times. Having completed the series at that dosage, we found that the incidence of movements of the patients was greater than that occurring in the buthalitone series (table II) . This suggested that, in some respects, the dosage was too low and it was increased to 30, 35 and 40 mg per stone in subsequent series in order to try to obtain a series in which the incidence of movements was comparable to that of the buthalitone series.
As before, the "waking", "sitting" and "standing" times were observed. These were recorded to the nearest half-minute and were measured from the conclusion of the anaesthesia. The waking time was that at which the patient was sufficiently awake to answer simple questions. The sitting time was when the patient could sit up unaided and the standing time was when he or she could stand and walk unaided.
Records were also made of the incidence of movements, vomiting, cough, hiccup and laryngeal spasm. Movements were classified as "slight" when they caused no interference with the operation; "moderate" when, with a moderate degree of restraint, the operation could be continued satisfactorily; and "severe" when the operating had to be interrupted so that the patient could be quietened.
In 40 cases (20 with each drug, selected at random) electrocardiograms were performed to see whether there was any toxic effect on the myocardium with the doses used in the present series and, if so, whether there was any difference in the incidence of electrocardiographic changes between the two drugs.
In order to exclude as many variable factors as possible in the five series, all patients had the same premedication of atropine (0.64 mg) half an hour before operation. A 10 ml all-glass syringe fitted with a size 12 needle was used and the injections of the thiobarbiturate were given as rapidly as possible. Buthalitone was used in a 10 per cent solution and thiopentone in a 5 per cent solution so that the volumes of solution injected were as nearly as possible the same. All injections were given and all observations made by the same person.
RESULTS AND DISCUSSION
The recovery times are shown in table I and the incidence of movements during operation in table E.
The first thiopentone series to be completed was that using a dosage of 25 mg per stone (6.3 kg) body weight. Although this rate of dosage was found to give average recovery times only slightly longer than those of the series receiving buthali- tone at the rate of 70 mg per stone body weight, the incidence of movements requiring restraint was 15 per cent as compared with 2 per cent of the cases receiving buthalitone. Similarly, in the series receiving 30 mg per stone body weight of thiopentone, the incidence of movements requiring restraint (9 per cent) was again greater than that of the buthalitone series and there was slight prolongation of the recovery times. These results were taken 4 as an indication that, although the average durations of anaesthesia in the thiopentone series were longer than those in the buthalitone series, the depth of anaesthesia produced by the thiopentone was less than that of the buthalitone. On the other hand, the two series receiving 35 and 40 mg per stone body weight of thiopentone had an incidence of movements requiring restraint inore nearly comparable with that of the buthalitone series. However, in the series receiving 40 mg per stone body weight, the average recovery times were considerably prolonged. These results would suggest that, with this dosage, some degree of saturation of the body fat depots probably occurs.
In comparing these results, we first had to determine whether there was any correlation between the duration of anaesthesia and the recovery (standing) time for each series. This was done and the correlation coefficient, r, was examined for significance by the t-test in each series. The results of this are shown in table HI. With 98 (100-2) dJ., the significant value of the correlation coefficient at the 5 per cent level is 0.195. It will therefore be seen that only the coefficients for the buthalitone and the 25 mg thiopentone series are significant at the 5 per cent level and that their value decreases with increasing dosage of thiopentone. This suggests that, with a small dose of thiopentone or buthalitone, when the duration of anaesthesia is prolonged the recovery time is influenced more by the effects of the nitrous oxide than those of the thiobarbiturate. On the other hand, the negative correlation coefficient with the 40 mg per stone thiopentone series indicates that there is a tendency for a longer, anaesthesia to be followed by a shorter recovery time. This can be explained on the supposition that, in those cases of short duration, the patient had still to recover from the effects of the thiopentone when the nitrous oxide administration had been stopped. Conversely, the effects of the thiopentone would be less after longer anaesthesia and recovery would be mainly from the effects of nitrous oxide anaesthesia. In view of these findings, it was felt that the comparison between the various doses of thiopentone and the buthalitone should be limited to those cases with a shorter duration of anaesthesia in order to limit as far as possible one variable factor. In the preliminary calculations, each series was split up into a group having a duration of up to 10 minutes and another comprising cases with a duration of 10i to 20 minutes. However, in each series, there was no significant difference between the two groups and so the final comparison is based on the results of cases where the duration of anaesthesia did not exceed 20 minutes. These figures are shown in table IV.
When these corrected average standing times of the thiopentone series are compared with that of the buthalitone series, only the differences between thiopentone 25 and 40 mg per stone and buthalitone are significant at the 5 per cent level when examined by the <-test (see table V).
The relationship between the recovery times for buthalitone and the thiopentone 25 mg per stone series may be explained by the fact that the thiopentone series has a longer average duration of anaesthesia than the buthalitone series and, with this dosage of thiopentone, both have a positive correlation between duration of anaesthesia and recovery time. In the case of the thiopentone 40 mg per stone series, it can probably be assumed that, in most of the patients, a partial saturation of the body fat with thiopentone has occurred.
If we now consider the incidence of movements during anaesthesia (table II) , we find that, with a dosage of thiopentone of 25 mg per stone body weight, there is an incidence of 18 per cent above that for buthalitone. Using the ^2 test, this is shown to be significant (0.01>p>0.001). This was also true of the incidence of moderate and severe movements only (movements requiring Significant Not significant Not significant Significant restraint) (0.001>p>0.0001). The incidence of movements requiring restraint in the 30 mg per stone thiopentone series was compared with that of the buthalitone series and was also found to be significantly increased (0.05>p>0.02). In all other cases there was no significant variation in the incidence of total movements and of movements requiring restraint. These results of the differences in standing times and the incidence of movements requiring restraint taken together suggest that the series receiving 35 mg per stone body weight of thiopentone most nearly compares with that receiving 70 mg per stone body weight of buthalitone. Thus in the 25 mg and 30 mg per stone thiopentone series, there is a significantly increased incidence of movements requiring restraint suggesting that the degree of anaesthesia is less than that attained with the buthalitone, while the greatly increased recovery time of the 40 mg per stone thiopentone series shows that the depth of anaesthesia is probably greater than that of the buthalitone series. Table VI shows the comparable rates of dosage in seven other published series comparing buthalitone with thiopentone. Our ratio of 1:2 of thiopentone to buthalitone is closely comparable to four of these seven series. In view of this fact, we feel that this method of assessing equipotent anaesthetic dosages could be employed usefully as a means of standardizing the potency of other thiobarbiturates and intravenous anaesthetic agents. Table VII shows the incidence of other sideeffects during and after anaesthesia. Vomiting occurred in 7 per cent of cases receiving buthalitone and in 11 per cent of the cases having 35 mg per stone body weight of thiopentone. Using the X 3 test, this difference and the differences between the other series were found to be statistically not significant. Two cases of laryngeal spasm occurred; one in each of the series with the higher dosages of thiopentone.
Influence of Sex.
Dundee (1954) has investigated the influence of various factors, including sex, upon the dosage of thiopentone. He found that males, on the If the corrected rates for the standing times are taken (where the duration of anaesthesia does not exceed 20 minutes) then in all the series except that receiving 25 mg per stone of thiopentone there is a significant increase in the standing times of female cases when compared with the corresponding male cases, the values of t varying from 1.97 to 2.72, which are all significant at the 5 per cent level.
If the results of each thiopentone series are broken down according to the sexes and these are then compared with the corresponding sex of the buthalitone series, it is found that the only male series which is not significantly different from the buthalitone series is that receiving 35 mg per stone of thiopentone. In the case of the female series, the only one significantly different from the buthalitone series is that receiving 40 mg per stone of thiopentone. Thus, once again, the 35 mg thiopentone series would appear to compare most closely with the 70 mg buthalitone series.
Electrocardiographs Changes.
Although a high incidence of electrocardiographic abnormalities has been noted following the administration of thiopentone to experimental animals (Gruber et al., 1938; Kohn and Lederer, 1938; Widenhom et al., 1938; Gruber, 1937 Gruber, , 1941 , the results in man have been variable. Volpitto and Marangoni (1938) reported on the abnormalities produced by thiopentone, hexobarbitone and thioethamyl. Of 11 administrations of thiopentone, there was slight tachycardia but no abnormalities of the QRS complex or of the PR interval. This absence of abnormalities was also noted by Rosner et al. (1953) who found none related to thiopentone alone but noted depression of ST and decreased voltage of T wave in the presence of hypopnoea. On the other hand, Carraway (1939) noted electrocardiographic changes in 22 out of 52 cases having thiopentone; Burstein et al. (1950) , 1 case out of 5; Stephen et al. (1953) who noted 37 instances of changes out of 238 cases when recordings were made immediately after induction with thiamylal, thiopentone and hexobarbitone; and Rollason and Hough (1958) who make a detailed report of the changes seen in 52 patients following induction with thiopentone. Johnstone (1951) , using a fixed dosage of 500 mg of thiopentone in a series of 100 cases, has noted an increase of sinus rate in patients who had no premedication and a decrease in rate in those who had 1.3 mg of atropine 20 minutes before induction. He also observed occasional decrease in voltage of P waves and of T waves.
Little work appears to have been done upon the electrocardiographic changes produced by buthalitone in man, but Weese and Koss (1954) report that no irregularities were observed in their experiments with dogs. Our technique for making the recordings was as follows. When the patient was lying on the table and the leads had been attached, a control tracing of leads I, II and III was made. A continuous tracing of lead II was made during the injection of the thiobarbiturate and this was continued for 30 seconds after the start of the injection. The facemask was then applied and the nitrous oxide and oxygen mixture administered. Tracings of leads I, II and HI were then made at 1 and 5 minutes after the start of the injection. Recordings of these three leads were continued at 5 minute intervals throughout the operation. A final tracing of leads I, II and HI was made shortly after the "waking time" had been observed. The results are shown in table IX. Sinus tachycardia (of 20/min or more) was seen frequently (9 cases with each drug) during and just after injection, but it was always transient. Occasional ventricular extrasystoles occurred shortly after injection in 3 patients receiving thiopentone; none were produced by buthalitone. The QT interval was prolonged in every case with both drugs. No abnormality of the PR interval, QRS complex or T wave was observed in any case.
SUMMARY
A short review of buthalitone sodium and the methods by which it has been compared with thiopentone is given.
A series of 100 cases receiving buthalitone has been compared with four series, each of 100 cases, given thiopentone in differing dosage rates.
By the technique described, buthalitone was found to require approximately twice the dose to produce an anaesthetic effect equivalent to that of thiopentone. This result has been compared with comparative studies by other workers. When buthalitone is used in twice the dosage of thiopentone, no significant difference in recovery times or side-effects between the two drugs was found.
It is suggested that the method described may be a useful means of comparing the potency of tbiobarbiturates and other intravenous anaesthetic agents.
The incidence of electrocardiographic abnormalities in 20 random cases with each drug is reported.
